# Bristol-Myers Squibb Co (BMY)

Bristol Myers Squibb's new schizophrenia drug Cobenfy (KarXT) is performing well, with Q4 [----] earnings showing its revenue surpassing 60% and Wall Street re-rating its valuation.

### About Bristol-Myers Squibb Co
Bristol-Myers Squibb Co. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines.  
Bristol-Myers Squibb Co uses the ticker $BMY for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Bristol-Myers Squibb Co (BMY) social dominance is up 49.55% from the previous [--] months.
- Bristol-Myers Squibb Co (BMY) sentiment is up 10.98% from the previous week.

### Price: $60.70
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/close.tsv)  
The stock is trading near its 52-week low due to patent cliff concerns, but recent positive clinical trial news and a surge in social media mentions indicate growing investor interest and a potential rebound.  

24-Hour: 0.99%
7-Day: -1.79%
30-Day: 9.92%

1-Year High: $63.10 on 2025-03-10  
1-Year Low: $42.60 on 2025-10-29  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/alt_rank.tsv)  
Bristol-Myers Squibb Co (BMY) is currently AltRank #424 based on combined combined social and market metrics
Daily Average: [---]  
[--] Week: [---] [---]  
[--] Month: [---] [---]  
[--] Months: [---] +171  
[--] Year: [---] +86  
1-Year High: [-----] on 2025-07-12  
1-Year Low: [--] on 2025-05-17  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +1  
[--] Month: [--] [---]  
[--] Months: [--] [---]  
[--] Year: [--] [---]  
1-Year High: [--] on 2025-07-16  
1-Year Low: [--] on 2025-05-21  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [------]  
[--] Week: [-------] -83%  
[--] Month: [---------] -43%  
[--] Months: [----------] +23%  
[--] Year: [----------] +3.90%  
1-Year High: [---------] on 2025-12-20  
1-Year Low: [------] on 2025-05-03  

Engagements by network (24h):
Instagram: [--]
News: [---]
TikTok: [---]
YouTube: [---]
Reddit: [--]
X: [------]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [---]  
[--] Week: [-----] -30%  
[--] Month: [-----] +100%  
[--] Months: [------] -27%  
[--] Year: [------] +0.78%  
1-Year High: [-----] on 2025-06-27  
1-Year Low: [---] on 2025-12-07  

Mentions by network (24h):
Instagram: [--]
News: [--]
TikTok: [--]
YouTube: [--]
Reddit: [--]
X: [---]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning Bristol-Myers Squibb Co (BMY) in the last [--] hours which is down 15% from [---] in the previous [--] hours
Daily Average: [---]  
[--] Week: [-----] -28%  
[--] Month: [-----] +87%  
[--] Months: [-----] -43%  
[--] Year: [------] +137%  
1-Year High: [-----] on 2025-06-27  
1-Year Low: [--] on 2025-12-07  

The most influential creators that mention Bristol-Myers Squibb Co in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@ProfesorDiv](/creator/twitter/ProfesorDiv)         | [--]    | [------]    | [--]     | [------]      |
| [@austinsayhi](/creator/twitter/austinsayhi)         | [--]    | [-----]     | [--]     | [-----]       |
| [@DimitryNakhla](/creator/twitter/DimitryNakhla)     | [--]    | [------]    | [--]     | [---]         |
| [@VoxVex000](/creator/twitter/VoxVex000)             | [--]    | [-----]     | [--]     | [---]         |
| [@HOThomasWPhelps](/creator/twitter/HOThomasWPhelps) | [--]    | [-----]     | [--]     | [---]         |
| [@doepke_michel](/creator/twitter/doepke_michel)     | [--]    | [-----]     | [--]     | [---]         |
| [@eWhispers](/creator/twitter/eWhispers)             | [--]    | [-------]   | [--]     | [---]         |
| [@Pharmdca](/creator/twitter/Pharmdca)               | [--]    | [-------]   | [--]     | [---]         |
| [@semodough](/creator/twitter/semodough)             | [--]    | [-----]     | [--]     | [---]         |
| [@EconomicTimes](/creator/twitter/EconomicTimes)     | [--]   | [---------] | [--]     | [---]         |

[View More](/list/creators/$bmy/100)
  
  
### Sentiment: 89%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/sentiment.tsv)  
Current Value: 89%  
Daily Average: 77%  
[--] Week: 91% +9%  
[--] Month: 81% -4%  
[--] Months: 81% -4%  
[--] Year: 81% +19%  
1-Year High: 98% on 2025-06-27  
1-Year Low: 50% on 2025-05-15  

Most Supportive Themes:
- Pipeline and Clinical Trial Updates: (40%) Bristol-Myers Squibb is presenting positive results from clinical trials for various treatments.
- Partnerships and Collaborations: (30%) Bristol-Myers Squibb is forming strategic alliances and collaborations to advance its drug development pipeline.
- Financial Performance and Earnings: (20%) Analysts are anticipating significant updates on Bristol-Myers Squibb's financials and pipeline progress.
  
Most Critical Themes:
- Patent Cliffs and Revenue Concerns: (40%) Bristol-Myers Squibb faces significant revenue challenges due to upcoming patent expirations for key drugs.
- Stock Performance and Valuation: (35%) The stock has experienced a significant decline, trading near its 52-week low.
- Layoffs and Restructuring: (25%) The company has announced significant layoffs as part of a broader cost-cutting strategy.
  
  
  
### Social Dominance: 0.035%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/social_dominance.tsv)  
Current Value: 0.035%  
Daily Average: 0.067%  
[--] Week: 0.033% +0.00748%  
[--] Month: 0.067% +0.016%  
[--] Months: 0.067% +0.0041%  
[--] Year: 0.067% -0.023%  
1-Year High: 0.226% on 2025-06-27  
1-Year Low: 0.023% on 2025-12-07  
  
  
### Market Dominance: 0.14%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/market_dominance.tsv)  
Current Value: 0.14%  
Daily Average: 0%  
1-Year High: 0.24% on 2025-03-12  
1-Year Low: 0.103% on 2025-10-29  
  
  
### Market Cap: $123,817,601,264
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$bmy/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$bmy/time-series/market_cap.tsv)  
Current Value: $123,817,601,264  
Daily Average: $102,429,899,175  
[--] Week: $123,104,835,467 -2.10%  
[--] Month: $123,695,412,842 +7.30%  
[--] Months: $123,695,412,842 +26%  
[--] Year: $123,695,412,842 +13%  
1-Year High: $128,433,949,919 on 2025-03-10  
1-Year Low: $86,723,078,950 on 2025-10-29  

### Top Bristol-Myers Squibb Co News
Top news links shared on social in the last [--] hours  

*Showing a maximum of [--] news posts without a LunarCrush subscription.*  

"Clot-Fighting Drug Plavix Set to Lose Patent Protection - The New York Times The drug which prevents clots among heart attack patients will no longer be promoted by Bristol-Myers Squibb because of an influx of cheaper generic alternatives"  
[News Link](https://www.nytimes.com/2012/05/17/business/plavix-set-to-lose-patent-protection.html) [@nytimes](/creator/x/nytimes) 2025-09-29T20:09Z 52.9M followers, 78.5K engagements



### Top Bristol-Myers Squibb Co Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"@ericjackson Ive had [--] losers YTD I cut them all quick - sold $HUM at $210 $NVO at $51 $BMNR at $30 All went down further Those funds I put into winners $BMY $CAG $UPS All of those are up Makes a massive difference cutting losers adding to winners"  
[X Link](https://x.com/JackLocks101/status/2022825426951757835) [@JackLocks101](/creator/x/JackLocks101) 2026-02-15T00:08Z [---] followers, [---] engagements


"They already exhausted FMR and a few other $VKTX institutions that get there on rumors and flash trial results. CEO is not helping in this regard as can burn shorts with an update on vanquish comparison to competitors etc. he seems very relaxed . may he seeing level of interest that we dont see . All doesnt matter even short term as $NVO $ABBV $BMY and probably $MRK reaching stress level to get a dual agonist. https://twitter.com/i/web/status/2022781015501259192 https://twitter.com/i/web/status/2022781015501259192"  
[X Link](https://x.com/bioinvestor24/status/2022781015501259192) [@bioinvestor24](/creator/x/bioinvestor24) 2026-02-14T21:12Z [----] followers, [---] engagements


"$BMY BMY [----] Q4  Cobenfy (KarXT) 60%  Bristol Myers Squibb $BMY is so bullish Why The essence of BMY's surge is its successful execution of a strategic pivot. The market initially feared it would perish at the patent cliff of its legacy drugs. However the Q4 [----] earnings report confirmed that its https://t.co/6Fx9TpzRxv Bristol Myers Squibb $BMY is so bullish Why The essence of BMY's surge is its successful execution of a strategic pivot. The market initially feared it would perish at the patent cliff of its legacy drugs. However the Q4 [----] earnings report confirmed that its"  
[X Link](https://x.com/VoxVex000/status/2022666204859773111) [@VoxVex000](/creator/x/VoxVex000) 2026-02-14T13:36Z [----] followers, [---] engagements


"Bristol Myers Squibb $BMY is so bullish Why The essence of BMY's surge is its successful execution of a strategic pivot. The market initially feared it would perish at the patent cliff of its legacy drugs. However the Q4 [----] earnings report confirmed that its next-generation schizophrenia drug Cobenfy (KarXT) is a blockbuster hit. Furthermore revenue from its new product portfolio has surpassed 60% forcing Wall Street to admit the mispricing and violently re-rate its valuation logic from a declining legacy pharma to a high-growth biopharma."  
[X Link](https://x.com/VoxVex000/status/2022665732811898903) [@VoxVex000](/creator/x/VoxVex000) 2026-02-14T13:34Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing